{
    "info": {
        "nct_id": "NCT04117945",
        "official_title": "A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)",
        "inclusion_criteria": "* Histologically proven, unresectable distant metastatic or locally advanced colorectal adenocarcinoma\n* KRAS, NRAS wild type\n* BRAF v600E wildtype\n* Measurable disease\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2\n* Life expectancy of >= 3 months per estimation of treating physician\n* Absolute neutrophil count (ANC) >= 1200/mm^3 (obtained =< 7 days prior to randomization)\n* Platelet count >= 75,000/mm^3 (obtained =< 7 days prior to randomization)\n* Hemoglobin >= 9.0 g/dL (obtained =< 7 days prior to randomization)\n* Total bilirubin =< 1.5 x upper limit of normal (ULN) (obtained =< 7 days prior to randomization)\n* Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) (obtained =< 7 days prior to randomization)\n* Serum creatinine =< 1.5 x ULN (obtained =< 7 days prior to randomization)\n* International normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN (obtained =< 7 days prior to randomization)\n\n  * NOTE: Patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care\n* Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for patients with liver involvement of their cancer) (obtained =< 7 days prior to randomization)\n* Negative serum pregnancy test done =< 7 days prior to randomization for women of childbearing potential only.\n\n  * NOTE: Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test. The definition of adequate contraception will be based on the judgment of the treating physician\n* Provide informed written consent\n* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\n* Disease progression on or intolerable to any of the following: fluoropyrimidine, oxaliplatin and irinotecan\n* Able to swallow and retain oral medication\n* Willing to provide tissue and blood samples for correlative research purposes\n* Willing to allow transfer of tissue and blood samples, clinical information, and outcome data collected from this trial for future research\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Prior treatment with regorafenib, cetuximab or panitumumab\n* Major surgical procedure, open biopsy, or significant traumatic injury =< 28 days prior to randomization\n* Congestive heart failure > New York Heart Association (NYHA) class 2.\n\n  * NOTE: Class 3 is defined as marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g., walking short distances (20-100m). They are comfortable at rest. Class 4 is defined as patients with severe limitations. Experiences symptoms even while at rest. Mostly bed bound\n* Unstable angina (angina symptoms at rest), new-onset angina (begun =< 3 months prior to randomization) or myocardial infarction =< 6 months prior to randomization\n* Cardiac arrhythmias requiring anti-arrhythmic therapy. Note: Pace makers, beta blockers or digoxin are permitted\n* Uncontrolled hypertension. (Systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg despite optimal medical management)\n* History of or current pheochromocytoma\n* Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism =< 6 months prior to randomization\n* Ongoing infection > grade 2 National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0\n* Known history of chronic hepatitis B or C\n* Patients with seizure disorder requiring medication\n* Symptomatic metastatic brain or meningeal tumors unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of randomization and is clinically stable with respect to the tumor at the time of randomization. Note: Patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable provided that the dose is stable for one month prior to and following screening radiographic studies)\n* History of organ allograft (including corneal transplant)\n* Evidence or history of bleeding diathesis or any hemorrhage or bleeding event > CTCAE v5.0 grade 3 =< 4 weeks prior to randomization\n* Non-healing wound, ulcer, or bone fracture\n* Substance abuse, medical, psychological or social conditions that may interfere with the patient?s participation in the study or evaluation of the study results\n* High-frequency microsatellite instability (MSI-H) patients who have not received prior PD-1 monoclonal antibody (mAb) therapy\n* Concurrent anti-cancer therapy =< 3 weeks from randomization (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization)\n* Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation\n* Interstitial lung disease with ongoing signs and symptoms at the time of informed consent\n* History of known persistent proteinuria of CTCAE v5.0 grade 3 or higher (>= 3.5 g/24 hrs)\n* Any malabsorption condition\n* Unresolved toxicity greater than CTCAE v5.0 grade 1 attributed to any prior therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity =< grade 2\n* Albumin levels < 2.5 g/dl\n* Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:\n\n  * Pregnant women\n  * Nursing women\n  * Men or women of childbearing potential who are unwilling to employ adequate contraception\n  * NOTE: Men and women of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 3 months after the last dose of study drug. The definition of adequate contraception will be based on the judgment of the principal investigator or a designated associate\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the treating physician, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Known history of human immunodeficiency virus (HIV) infection or active hepatitis B or C infection requiring treatment with antiviral therapy\n* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm\n* Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer =< 3 years prior to randomization EXCEPT for cervical cancer in-situ, treated ductal carcinoma in situ of the breast, curatively treated nonmelanoma skin carcinoma, noninvasive aerodigestive neoplasms, or superficial bladder tumor (Ta [Non-invasive tumor], Tis [carcinoma in situ] and T1 [Tumor invades lamina propria]). Note: All cancer treatments for cancers that were distinct in a primary site other than colorectal must be completed at least 3 years prior to randomization (i.e., signature date of the informed consent form)\n* Pleural effusion or ascites that causes respiratory compromise (>= CTCAE v5.0 grade 2 dyspnea)\n* Any condition which, in the treating physician?s opinion, makes the subject unsuitable for trial participation",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Histologically proven, unresectable distant metastatic or locally advanced colorectal adenocarcinoma",
            "criterions": [
                {
                    "exact_snippets": "Histologically proven",
                    "criterion": "colorectal adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": "histologically proven"
                        }
                    ]
                },
                {
                    "exact_snippets": "unresectable",
                    "criterion": "colorectal adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "resectability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "distant metastatic or locally advanced",
                    "criterion": "colorectal adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "disease_stage",
                            "expected_value": [
                                "distant metastatic",
                                "locally advanced"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* KRAS, NRAS wild type",
            "criterions": [
                {
                    "exact_snippets": "KRAS ... wild type",
                    "criterion": "KRAS gene status",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "wild type"
                        }
                    ]
                },
                {
                    "exact_snippets": "NRAS wild type",
                    "criterion": "NRAS gene status",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "wild type"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of >= 3 months per estimation of treating physician",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of >= 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "per estimation of treating physician",
                    "criterion": "treating physician estimation",
                    "requirements": [
                        {
                            "requirement_type": "estimation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1200/mm^3 (obtained =< 7 days prior to randomization)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1200/mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1200,
                                "unit": "mm^3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 7 days prior to randomization",
                    "criterion": "ANC laboratory value timing",
                    "requirements": [
                        {
                            "requirement_type": "time from laboratory value to randomization",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count >= 75,000/mm^3 (obtained =< 7 days prior to randomization)",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >= 75,000/mm^3 (obtained =< 7 days prior to randomization)",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "mm^3"
                            }
                        },
                        {
                            "requirement_type": "measurement recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* BRAF v600E wildtype",
            "criterions": [
                {
                    "exact_snippets": "BRAF v600E wildtype",
                    "criterion": "BRAF v600E mutation status",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "wildtype"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin >= 9.0 g/dL (obtained =< 7 days prior to randomization)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 7 days prior to randomization",
                    "criterion": "hemoglobin measurement date",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 x upper limit of normal (ULN) (obtained =< 7 days prior to randomization)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 x upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 7 days prior to randomization",
                    "criterion": "total bilirubin measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "time before randomization",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine =< 1.5 x ULN (obtained =< 7 days prior to randomization)",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine =< 1.5 x ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 7 days prior to randomization",
                    "criterion": "serum creatinine measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "time before randomization",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN (obtained =< 7 days prior to randomization)",
            "criterions": [
                {
                    "exact_snippets": "International normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN (obtained =< 7 days prior to randomization)",
                    "criterion": "International normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "International normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN (obtained =< 7 days prior to randomization)",
                    "criterion": "partial thromboplastin time (PTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care",
            "criterions": [
                {
                    "exact_snippets": "therapeutically treated with an agent such as warfarin or heparin will be allowed to participate",
                    "criterion": "therapeutic anticoagulant treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "agent",
                            "expected_value": [
                                "warfarin",
                                "heparin"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "no prior evidence of underlying abnormality in coagulation parameters exists",
                    "criterion": "coagulation parameters",
                    "requirements": [
                        {
                            "requirement_type": "abnormality",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care",
                    "criterion": "INR/PTT stability",
                    "requirements": [
                        {
                            "requirement_type": "monitoring frequency",
                            "expected_value": "at least weekly"
                        },
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "measurement timing",
                            "expected_value": "pre-dose"
                        },
                        {
                            "requirement_type": "standard",
                            "expected_value": "local standard of care"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for patients with liver involvement of their cancer) (obtained =< 7 days prior to randomization)",
            "criterions": [
                {
                    "exact_snippets": "Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for patients with liver involvement of their cancer)",
                    "criterion": "alkaline phosphatase",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (for patients with liver involvement of their cancer)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 7 days prior to randomization",
                    "criterion": "alkaline phosphatase measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days prior to randomization"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Provide informed written consent",
            "criterions": [
                {
                    "exact_snippets": "Provide informed written consent",
                    "criterion": "informed written consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test. The definition of adequate contraception will be based on the judgment of the treating physician",
            "criterions": [
                {
                    "exact_snippets": "Post-menopausal women (defined as no menses for at least 1 year) ... are not required to undergo a pregnancy test",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "post-menopausal"
                        },
                        {
                            "requirement_type": "no menses duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "surgically sterilized women are not required to undergo a pregnancy test",
                    "criterion": "surgical sterilization status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "surgically sterilized"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)",
            "criterions": [
                {
                    "exact_snippets": "Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)",
                    "criterion": "willingness to return for follow-up",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "enrolling institution"
                        },
                        {
                            "requirement_type": "phase",
                            "expected_value": "active monitoring phase of the study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Negative serum pregnancy test done =< 7 days prior to randomization for women of childbearing potential only.",
            "criterions": [
                {
                    "exact_snippets": "Negative serum pregnancy test ... =< 7 days prior to randomization ... for women of childbearing potential only",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to randomization"
                            }
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "women of childbearing potential only"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing to provide tissue and blood samples for correlative research purposes",
            "criterions": [
                {
                    "exact_snippets": "Willing to provide tissue ... for correlative research purposes",
                    "criterion": "tissue sample provision",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Willing to provide ... blood samples for correlative research purposes",
                    "criterion": "blood sample provision",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing to allow transfer of tissue and blood samples, clinical information, and outcome data collected from this trial for future research",
            "criterions": [
                {
                    "exact_snippets": "Willing to allow transfer of tissue and blood samples, clinical information, and outcome data collected from this trial for future research",
                    "criterion": "willingness to allow transfer of samples and data for future research",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Able to swallow and retain oral medication",
            "criterions": [
                {
                    "exact_snippets": "Able to swallow and retain oral medication",
                    "criterion": "ability to swallow oral medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Able to swallow and retain oral medication",
                    "criterion": "ability to retain oral medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Disease progression on or intolerable to any of the following: fluoropyrimidine, oxaliplatin and irinotecan",
            "criterions": [
                {
                    "exact_snippets": "Disease progression on ... fluoropyrimidine",
                    "criterion": "fluoropyrimidine treatment",
                    "requirements": [
                        {
                            "requirement_type": "disease progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intolerable to ... fluoropyrimidine",
                    "criterion": "fluoropyrimidine treatment",
                    "requirements": [
                        {
                            "requirement_type": "tolerability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Disease progression on ... oxaliplatin",
                    "criterion": "oxaliplatin treatment",
                    "requirements": [
                        {
                            "requirement_type": "disease progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intolerable to ... oxaliplatin",
                    "criterion": "oxaliplatin treatment",
                    "requirements": [
                        {
                            "requirement_type": "tolerability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Disease progression on ... irinotecan",
                    "criterion": "irinotecan treatment",
                    "requirements": [
                        {
                            "requirement_type": "disease progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intolerable to ... irinotecan",
                    "criterion": "irinotecan treatment",
                    "requirements": [
                        {
                            "requirement_type": "tolerability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Unstable angina (angina symptoms at rest), new-onset angina (begun =< 3 months prior to randomization) or myocardial infarction =< 6 months prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "Unstable angina (angina symptoms at rest)",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "new-onset angina (begun =< 3 months prior to randomization)",
                    "criterion": "new-onset angina",
                    "requirements": [
                        {
                            "requirement_type": "onset_time_before_randomization",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction =< 6 months prior to randomization",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "event_time_before_randomization",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Substance abuse, medical, psychological or social conditions that may interfere with the patient?s participation in the study or evaluation of the study results",
            "criterions": [
                {
                    "exact_snippets": "Substance abuse ... may interfere with the patient?s participation in the study or evaluation of the study results",
                    "criterion": "substance abuse",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study participation or evaluation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "medical ... conditions that may interfere with the patient?s participation in the study or evaluation of the study results",
                    "criterion": "medical conditions",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study participation or evaluation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "psychological ... conditions that may interfere with the patient?s participation in the study or evaluation of the study results",
                    "criterion": "psychological conditions",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study participation or evaluation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "social conditions that may interfere with the patient?s participation in the study or evaluation of the study results",
                    "criterion": "social conditions",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study participation or evaluation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unresolved toxicity greater than CTCAE v5.0 grade 1 attributed to any prior therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity =< grade 2",
            "criterions": [
                {
                    "exact_snippets": "Unresolved toxicity greater than CTCAE v5.0 grade 1 attributed to any prior therapy/procedure",
                    "criterion": "unresolved toxicity from prior therapy/procedure",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE v5.0 grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "excluding alopecia",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "excluding ... oxaliplatin induced neurotoxicity =< grade 2",
                    "criterion": "oxaliplatin induced neurotoxicity",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "CTCAE v5.0 grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:",
            "criterions": [
                {
                    "exact_snippets": "agent that has known genotoxic, mutagenic and teratogenic effects",
                    "criterion": "study agent",
                    "requirements": [
                        {
                            "requirement_type": "genotoxicity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "mutagenicity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "teratogenicity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Congestive heart failure > New York Heart Association (NYHA) class 2.",
            "criterions": [
                {
                    "exact_snippets": "Congestive heart failure > New York Heart Association (NYHA) class 2",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "NYHA class"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Nursing women",
            "criterions": [
                {
                    "exact_snippets": "Nursing women",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "nursing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled hypertension. (Systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg despite optimal medical management)",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension. (Systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg despite optimal medical management)",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Systolic blood pressure > 140 mmHg ... despite optimal medical management",
                    "criterion": "systolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 140,
                                "unit": "mmHg"
                            }
                        },
                        {
                            "requirement_type": "despite_optimal_medical_management",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "diastolic pressure > 90 mmHg ... despite optimal medical management",
                    "criterion": "diastolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "mmHg"
                            }
                        },
                        {
                            "requirement_type": "despite_optimal_medical_management",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Albumin levels < 2.5 g/dl",
            "criterions": [
                {
                    "exact_snippets": "Albumin levels < 2.5 g/dl",
                    "criterion": "albumin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "g/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any condition which, in the treating physician?s opinion, makes the subject unsuitable for trial participation",
            "criterions": [
                {
                    "exact_snippets": "Any condition which, in the treating physician?s opinion, makes the subject unsuitable for trial participation",
                    "criterion": "any condition making subject unsuitable for trial participation",
                    "requirements": [
                        {
                            "requirement_type": "treating physician's opinion of suitability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with seizure disorder requiring medication",
            "criterions": [
                {
                    "exact_snippets": "seizure disorder requiring medication",
                    "criterion": "seizure disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requires medication",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Men or women of childbearing potential who are unwilling to employ adequate contraception",
            "criterions": [
                {
                    "exact_snippets": "Men or women of childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unwilling to employ adequate contraception",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-healing wound, ulcer, or bone fracture",
            "criterions": [
                {
                    "exact_snippets": "Non-healing wound",
                    "criterion": "wound",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "non-healing"
                        }
                    ]
                },
                {
                    "exact_snippets": "ulcer",
                    "criterion": "ulcer",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "non-healing"
                        }
                    ]
                },
                {
                    "exact_snippets": "bone fracture",
                    "criterion": "bone fracture",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "non-healing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ongoing infection > grade 2 National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0",
            "criterions": [
                {
                    "exact_snippets": "Ongoing infection > grade 2 National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0",
                    "criterion": "ongoing infection",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "grade (NCI-CTCAE v5.0)"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to any of the study drugs",
                    "criterion": "hypersensitivity to study drugs",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity to ... study drug classes",
                    "criterion": "hypersensitivity to study drug classes",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity to ... excipients in the formulation",
                    "criterion": "hypersensitivity to excipients in the formulation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any malabsorption condition",
            "criterions": [
                {
                    "exact_snippets": "Any malabsorption condition",
                    "criterion": "malabsorption condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic metastatic brain or meningeal tumors unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of randomization and is clinically stable with respect to the tumor at the time of randomization. Note: Patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable provided that the dose is stable for one month prior to and following screening radiographic studies)",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic metastatic brain or meningeal tumors",
                    "criterion": "symptomatic metastatic brain or meningeal tumors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "> 6 months from definitive therapy",
                    "criterion": "time since definitive therapy for brain or meningeal tumors",
                    "requirements": [
                        {
                            "requirement_type": "duration since therapy",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "negative imaging study within 4 weeks of randomization",
                    "criterion": "imaging study for brain or meningeal tumors",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "time since imaging",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically stable with respect to the tumor at the time of randomization",
                    "criterion": "clinical stability of brain or meningeal tumor",
                    "requirements": [
                        {
                            "requirement_type": "clinical stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must not be undergoing acute steroid therapy or taper",
                    "criterion": "acute steroid therapy or taper",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic steroid therapy is acceptable provided that the dose is stable for one month prior to and following screening radiographic studies",
                    "criterion": "chronic steroid therapy dose stability",
                    "requirements": [
                        {
                            "requirement_type": "dose stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* High-frequency microsatellite instability (MSI-H) patients who have not received prior PD-1 monoclonal antibody (mAb) therapy",
            "criterions": [
                {
                    "exact_snippets": "High-frequency microsatellite instability (MSI-H) patients",
                    "criterion": "microsatellite instability status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "MSI-H"
                        }
                    ]
                },
                {
                    "exact_snippets": "who have not received prior PD-1 monoclonal antibody (mAb) therapy",
                    "criterion": "prior PD-1 monoclonal antibody therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm",
            "criterions": [
                {
                    "exact_snippets": "Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm",
                    "criterion": "receipt of other investigational agent for primary neoplasm",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the treating physician, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens",
            "criterions": [
                {
                    "exact_snippets": "Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the treating physician, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens",
                    "criterion": "co-morbid systemic illnesses or other severe concurrent disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "physician judgment of appropriateness for study entry",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "physician judgment of interference with assessment of safety and toxicity",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Class 3 is defined as marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g., walking short distances (20-100m). They are comfortable at rest. Class 4 is defined as patients with severe limitations. Experiences symptoms even while at rest. Mostly bed bound",
            "criterions": [
                {
                    "exact_snippets": "Class 3 is defined as marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g., walking short distances (20-100m). They are comfortable at rest.",
                    "criterion": "functional status (Class 3)",
                    "requirements": [
                        {
                            "requirement_type": "limitation in activity",
                            "expected_value": "marked limitation due to symptoms during less-than-ordinary activity (e.g., walking 20-100m)"
                        },
                        {
                            "requirement_type": "symptoms at rest",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Class 4 is defined as patients with severe limitations. Experiences symptoms even while at rest. Mostly bed bound",
                    "criterion": "functional status (Class 4)",
                    "requirements": [
                        {
                            "requirement_type": "limitation in activity",
                            "expected_value": "severe limitations"
                        },
                        {
                            "requirement_type": "symptoms at rest",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "bed bound",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer =< 3 years prior to randomization EXCEPT for cervical cancer in-situ, treated ductal carcinoma in situ of the breast, curatively treated nonmelanoma skin carcinoma, noninvasive aerodigestive neoplasms, or superficial bladder tumor (Ta [Non-invasive tumor], Tis [carcinoma in situ] and T1 [Tumor invades lamina propria]). Note: All cancer treatments for cancers that were distinct in a primary site other than colorectal must be completed at least 3 years prior to randomization (i.e., signature date of the informed consent form)",
            "criterions": [
                {
                    "exact_snippets": "Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer =< 3 years prior to randomization",
                    "criterion": "previous or concurrent cancer distinct from colorectal cancer",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis or treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "distinctness",
                            "expected_value": "distinct in primary site or histology from colorectal cancer"
                        }
                    ]
                },
                {
                    "exact_snippets": "EXCEPT for cervical cancer in-situ, treated ductal carcinoma in situ of the breast, curatively treated nonmelanoma skin carcinoma, noninvasive aerodigestive neoplasms, or superficial bladder tumor (Ta [Non-invasive tumor], Tis [carcinoma in situ] and T1 [Tumor invades lamina propria])",
                    "criterion": "history of specific low-risk cancers",
                    "requirements": [
                        {
                            "requirement_type": "cancer type",
                            "expected_value": [
                                "cervical cancer in-situ",
                                "treated ductal carcinoma in situ of the breast",
                                "curatively treated nonmelanoma skin carcinoma",
                                "noninvasive aerodigestive neoplasms",
                                "superficial bladder tumor (Ta, Tis, T1)"
                            ]
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "All cancer treatments for cancers that were distinct in a primary site other than colorectal must be completed at least 3 years prior to randomization",
                    "criterion": "completion of cancer treatment for non-colorectal primary cancers",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment completion",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "primary site",
                            "expected_value": "other than colorectal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgical procedure, open biopsy, or significant traumatic injury =< 28 days prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "Major surgical procedure, open biopsy, or significant traumatic injury =< 28 days prior to randomization",
                    "criterion": "major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "open biopsy ... =< 28 days prior to randomization",
                    "criterion": "open biopsy",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "significant traumatic injury =< 28 days prior to randomization",
                    "criterion": "significant traumatic injury",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of human immunodeficiency virus (HIV) infection or active hepatitis B or C infection requiring treatment with antiviral therapy",
            "criterions": [
                {
                    "exact_snippets": "Known history of human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis B or C infection requiring treatment with antiviral therapy",
                    "criterion": "hepatitis B or C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring antiviral therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant women",
            "criterions": [
                {
                    "exact_snippets": "Pregnant women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent anti-cancer therapy =< 3 weeks from randomization (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization)",
            "criterions": [
                {
                    "exact_snippets": "Concurrent anti-cancer therapy =< 3 weeks from randomization (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization)",
                    "criterion": "concurrent anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with regorafenib, cetuximab or panitumumab",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with regorafenib",
                    "criterion": "prior treatment with regorafenib",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... cetuximab",
                    "criterion": "prior treatment with cetuximab",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... panitumumab",
                    "criterion": "prior treatment with panitumumab",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of or current pheochromocytoma",
            "criterions": [
                {
                    "exact_snippets": "History of or current pheochromocytoma",
                    "criterion": "pheochromocytoma",
                    "requirements": [
                        {
                            "requirement_type": "history or current diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence or history of bleeding diathesis or any hemorrhage or bleeding event > CTCAE v5.0 grade 3 =< 4 weeks prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "Evidence or history of bleeding diathesis",
                    "criterion": "bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any hemorrhage or bleeding event > CTCAE v5.0 grade 3 =< 4 weeks prior to randomization",
                    "criterion": "hemorrhage or bleeding event",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "CTCAE v5.0 grade"
                            }
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cardiac arrhythmias requiring anti-arrhythmic therapy. Note: Pace makers, beta blockers or digoxin are permitted",
            "criterions": [
                {
                    "exact_snippets": "Cardiac arrhythmias requiring anti-arrhythmic therapy",
                    "criterion": "cardiac arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "requirement for anti-arrhythmic therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Men and women of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 3 months after the last dose of study drug. The definition of adequate contraception will be based on the judgment of the principal investigator or a designated associate",
            "criterions": [
                {
                    "exact_snippets": "Men and women of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 3 months after the last dose of study drug.",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "from signing of ICF"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "months after last dose of study drug"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Men and women of childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Interstitial lung disease with ongoing signs and symptoms at the time of informed consent",
            "criterions": [
                {
                    "exact_snippets": "Interstitial lung disease with ongoing signs and symptoms at the time of informed consent",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ongoing signs and symptoms",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the time of informed consent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pleural effusion or ascites that causes respiratory compromise (>= CTCAE v5.0 grade 2 dyspnea)",
            "criterions": [
                {
                    "exact_snippets": "Pleural effusion or ascites that causes respiratory compromise (>= CTCAE v5.0 grade 2 dyspnea)",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "respiratory compromise",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "CTCAE v5.0 grade of dyspnea"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Pleural effusion or ascites that causes respiratory compromise (>= CTCAE v5.0 grade 2 dyspnea)",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "respiratory compromise",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "CTCAE v5.0 grade of dyspnea"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of known persistent proteinuria of CTCAE v5.0 grade 3 or higher (>= 3.5 g/24 hrs)",
            "criterions": [
                {
                    "exact_snippets": "History of known persistent proteinuria ... CTCAE v5.0 grade 3 or higher (>= 3.5 g/24 hrs)",
                    "criterion": "proteinuria",
                    "requirements": [
                        {
                            "requirement_type": "persistence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "CTCAE v5.0 grade"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3.5,
                                "unit": "g/24 hrs"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of organ allograft (including corneal transplant)",
            "criterions": [
                {
                    "exact_snippets": "History of organ allograft (including corneal transplant)",
                    "criterion": "organ allograft history",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism =< 6 months prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "Arterial or venous thrombotic or embolic events ... =< 6 months prior to randomization",
                    "criterion": "arterial or venous thrombotic or embolic events",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cerebrovascular accident (including transient ischemic attacks) ... =< 6 months prior to randomization",
                    "criterion": "cerebrovascular accident (including transient ischemic attacks)",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "deep vein thrombosis ... =< 6 months prior to randomization",
                    "criterion": "deep vein thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "pulmonary embolism ... =< 6 months prior to randomization",
                    "criterion": "pulmonary embolism",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to randomization"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) (obtained =< 7 days prior to randomization)",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ... =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) (obtained =< 7 days prior to randomization)",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "time of measurement",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days prior to randomization"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate amino-transferase (AST) ... =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) (obtained =< 7 days prior to randomization)",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "time of measurement",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days prior to randomization"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "= < 5 x ULN for subjects with liver involvement of their cancer",
                    "criterion": "ALT or AST level in subjects with liver involvement of their cancer",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "time of measurement",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days prior to randomization"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "* Known history of chronic hepatitis B or C",
            "criterions": [
                {
                    "exact_snippets": "Known history of chronic hepatitis B",
                    "criterion": "chronic hepatitis B",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known history of chronic hepatitis C",
                    "criterion": "chronic hepatitis C",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}